Risperidone is NOT appropriate for treating substance cravings
Risperidone is not indicated for the treatment of substance cravings and should not be used for this purpose. The available evidence shows that risperidone may actually worsen cravings in some contexts, particularly for cannabis, and there is no established therapeutic benefit for treating substance use disorders.
Evidence Against Use for Cravings
Cannabis Cravings - Risperidone Performs Poorly
The research directly comparing antipsychotics shows that risperidone is associated with significantly higher cannabis craving compared to both clozapine and olanzapine 1. In patients with psychotic disorders and cannabis dependence, those treated with risperidone reported substantially more craving than those on clozapine (p = .001) or olanzapine (p = .025) 1. This suggests risperidone may actually exacerbate rather than reduce cannabis cravings.
Cocaine - Limited and Conflicting Evidence
While one small open-label study (n=16) suggested risperidone might reduce cocaine craving in patients with comorbid psychiatric disorders 2, and another experimental study showed it reduced cocaine-induced euphoria 3, these findings are:
- From very small samples
- Not replicated in controlled trials
- Contradicted by a Cochrane review finding no clear differences between risperidone and other antipsychotics for reducing substance use 4
The comparison study between olanzapine and risperidone showed a trend toward greater cocaine reduction with olanzapine, not risperidone 5.
What Risperidone IS Indicated For
According to FDA labeling, risperidone is approved for 6:
- Schizophrenia (adults and adolescents)
- Bipolar mania (adults and pediatrics)
- Irritability associated with autistic disorder (pediatrics)
None of these indications include substance cravings or substance use disorders.
Evidence-Based Alternatives for Substance Cravings
For actual treatment of substance cravings, the evidence supports 7, 8:
For opioid use disorders:
- Buprenorphine (FDA-approved for ages 16+)
- Methadone
- Naltrexone (including extended-release formulation)
For alcohol use disorders:
- Acamprosate
- Naltrexone
- Topiramate (off-label but evidence-supported) 9
For tobacco:
- Nicotine replacement therapy
- Bupropion
- Varenicline
Critical Caveat
If a patient has co-occurring psychosis or bipolar disorder AND substance use disorder, risperidone may be appropriate for treating the primary psychiatric condition 10. The typical dose for early psychosis is 2 mg/day 10. However, the goal would be treating the psychotic symptoms, not the substance cravings themselves. In fact, clinicians should monitor for potentially increased cannabis cravings when using risperidone in this population 1.
The bottom line: Do not prescribe risperidone specifically to treat substance cravings. Use evidence-based medication-assisted treatments appropriate for the specific substance involved.